Lercanidipine Hydrochloride Accord-Uk (Lercanidipine Hydrochloride)

Lercanidipine is indicated for the management of hypertension, a condition characterized by elevated arterial pressure.

• Essential hypertension: lowers sustained high blood pressure in patients with primary hypertension.
• Isolated systolic hypertension: reduces systolic pressure in elderly patients with elevated systolic readings.
• Hypertensive urgency (adjunct): may be used as part of combination therapy to achieve target blood pressure.

• Lercanidipine selectively inhibits the influx of calcium ions through L‑type voltage‑gated calcium channels located on vascular smooth‑muscle cells. By blocking these channels, it prevents calcium‑dependent contraction, leading to relaxation of arterial smooth muscle, vasodilation, and a consequent decrease in peripheral vascular resistance and arterial blood pressure. The drug shows high affinity for the cardiovascular system and minimal effect on cardiac conduction, which contributes to its favorable tolerability profile.

Lercanidipine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate headache occurring early in therapy.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness: sensation of light‑headedness, especially upon standing.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure leading to fainting.
• Hepatotoxicity: abnormal liver function tests indicating possible liver injury.
• Allergic reactions: rash, pruritus, or anaphylaxis in rare cases.

When prescribing lercanidipine, clinicians should consider several precautionary measures to ensure safe use.

• Patient assessment: evaluate baseline blood pressure and cardiovascular status before initiating therapy.
• Concomitant therapy: review other antihypertensive agents to avoid excessive hypotension.
• Renal/hepatic function: adjust use in patients with severe impairment as metabolism may be altered.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks, due to limited safety data.
• Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Lercanidipine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension.
• Grapefruit juice: can markedly raise lercanidipine levels, leading to enhanced blood pressure lowering.

Moderate Interactions (Monitor Closely)

• Other antihypertensives (e.g., ACE inhibitors, diuretics): may cause additive blood pressure reduction.
• Simvastatin: lercanidipine can increase simvastatin exposure, requiring dose adjustment.
• Beta‑blockers: combined use may increase risk of bradycardia and dizziness.